Brainstorm Cell Therapeutics Inc. (BCLI)

Brainstorm Cell Therapeutics Inc. (OTC:BCLI) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Alla Patlis - Interim CFO & Controller Chaim Lebovits - President & CEO Ibrahim Dagher - Executive VP & Chief Medical Officer Conference Call Participants David Bautz - Zacks Small-Cap Research Michael Wood - Lifesci Advisors, LLC Operator Greetings, and welcome to the Brainstorm Cell Therapeutics Second Quarter 2025 Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK , Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update.

Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK , Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the second quarter of 2025, at 8.30 a.m. Eastern Time on August 14, 2025.

NEW YORK , July 17, 2025 BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it has received a delisting notification from The Nasdaq Stock Market LLC, informing the company that its common stock will be delisted from the Nasdaq Capital Market. Trading of BrainStorm's common stock on Nasdaq will be suspended at the open of trading on July 18, 2025.

BrainStorm to Continue with Planned Phase 3b Trial and Remains Committed to Advancing Access for People Living with ALS NEW YORK , July 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today acknowledged that the U.S. Food and Drug Administration's (FDA) consideration of a Citizen Petition requesting a new review of the data supporting NurOwn will provide a critical opportunity to reaffirm its potential as therapy for amyotrophic lateral sclerosis (ALS). A Citizen Petition, submitted to the FDA under the Federal Food, Drug, and Cosmetic Act (21 CFR § 10.30), is a regulatory process that allows any interested party to formally request the Agency to take action on specific matters, such as reviewing data, issuing new guidance, or taking enforcement action.

NEW YORK , June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its Expanded Access Program (EAP) for NurOwn® (autologous MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The EAP enrolled 10 participants who had previously completed the Phase 3 clinical trial.

NEW YORK , May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Joyce Lonergan - Investor Relations, LifeSci Advisors Chaim Lebovits - President & Chief Executive Officer Haro Hartounian - Executive Vice President & Chief Operating Officer Bob Dagher - Executive Vice President & Chief Medical Officer Netta Blondheim-Shraga - Senior Vice President, Research & Development Conference Call Participants Jason McCarthy - Maxim Group David Bautz - Zacks Small-Cap Operator Greetings, and welcome to the Brainstorm Cell Therapeutics First Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode.

Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK , May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).

Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK , May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.

NEW YORK , May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has rescheduled the release of its financial results for the first quarter ended March 31, 2025, to post-market close today, May 15. In addition, the Company has rescheduled its previously announced investor conference call, which will now take place on Monday, May 19, 2025, at 8:30 a.m.

NEW YORK , May 7, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2025, and provide a corporate update, at 8:30 a.m. Eastern Time on Thursday, May 15, 2025.

Presentation of biomarker findings from cerebrospinal fluid analyses Workshop on adaptive and decentralized ALS trial design Panel on clinical trial access and the role of patient and caregiver engagement NEW YORK , May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in the 4th Annual ALS Drug Development Summit, to take place May 12-14, 2025, in Boston, MA. The company's senior leadership team will participate in sessions that highlight insights and expertise gained throughout the NurOwn® development program, contributing to the broader conversation on the future of ALS clinical research.

New findings highlight impact of UNC13A genotype on treatment response in ALS NEW YORK , April 29, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with leading ALS research centers, today announced the acceptance of new pharmacogenomic data for oral presentation of new findings on NurOwn® at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, to take place from May 6 - 10, 2025 in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for amyotrophic lateral sclerosis (ALS) patients treated with NurOwn® (debamestrocel).

NEW YORK , April 10, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) for NurOwn®, the company's autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (ALS). This important milestone sets the stage for the initiation of BrainStorm's highly anticipated Phase 3b clinical trial, which has been designed in collaboration with the FDA under a Special Protocol Assessment (SPA).

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Michael Wood - Investor Relations Chaim Lebovits - President & Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Bob Dagher - Executive Vice President & Chief Medical Officer Haro Hartounian - Executive Vice President & Chief Operating Officer Conference Call Participants Jason McCarthy - Maxim Group David Bautz - Zacks Small-Cap Operator Good morning, everyone, and welcome to BrainStorm Cell Therapeutics Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.